Therapeutics

Physostigmine Salicylate

Tools

Back to the Top

Overview

Name: Physostigmine Salicylate
Synonyms: Synapton
Therapy Type: Small Molecule (timeline)
Target Type: Cholinergic System (timeline)
Condition(s): Alzheimer's Disease
U.S. FDA Status: Alzheimer's Disease (Discontinued)
Company: Forest Laboratories, Inc.

Background

Physostigmine salicylate is a reversible acetylcholinesterase inhibitor that effectively increases the concentration of acetylcholine and thus the stimulation of both nicotinic and muscarinic receptors due to the increase in available acetylcholine at the synapse.

Last Updated: 11 Apr 2013

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.

References

No Available References

Further Reading

No Available Further Reading